Mumbai, June 24 (UNI) Biocon Biologics Limited, a fully integrated global biosimilars company, on Tuesday said that it has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.

Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment

and medicine supply as part of its healthcare services.

This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia, Biocon said in a filing with BSE on Tuesday.

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints.

The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.

Ratish Trehan, Head of Commercial - Emerging Markets, Biocon Biologics, said, "Our partnership with the National Cancer Society of Malaysia marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need. This collaboration, which combines our scientific expertise with NCSM's strong community outreach and patient support network, aims to ease the treatment burden for underserved populations. Together, we hope to positively impact thousands of lives and strengthen Malaysia's efforts to deliver inclusive, patient-centric healthcare."

Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this.

Ratish Trehan, Head of Commercial - Emerging Markets, Biocon Biologics, and Dato' Dr. Saunthari Somasundaram, President of NCSM, signed the MoU, on the sidelines of the National Cancer Congress Malaysia 2025, held in June in Kuala Lumpur, in the presence of Datuk Seri Dr Dzulkefly Ahmad, Minister of Health, Malaysia.

UNI JS BM